Functional Impact of a Single-nucleotide Polymorphism in the OPRD1 Promoter Region

Overview

Journal J Hum Genet

Specialty Genetics

Date 2010 Mar 20

PMID 20300121

Citations 15

Authors

Huiping Zhang

Joel Gelernter

Jeffrey R Gruen

Henry R Kranzler

Aryeh I Herman

Arthur A Simen

Affiliations

Soon will be listed here.

Abstract

The delta-opioid receptor mediates rewarding effects of many substances of abuse. We reported an increased frequency of the minor G-allele of single-nucleotide polymorphism (SNP) rs569356 (the only variant identified so far in the promoter region of the delta-opioid receptor gene (OPRD1)) in subjects with opioid dependence. In this study, we examined the functional significance of this variant. OPRD1 promoter region harboring SNP rs569356 was amplified by PCR and inserted into a firefly luciferase reporter vector. HEK293 cells were co-transfected with these constructs and a renilla luciferase vector to control for transfection efficiency. Expression of firefly luciferase (driven by the OPRD1 promoter) was measured by a dual luciferase reporter assay and normalized by renilla luciferase expression. Moreover, alleles altering expression were further assessed for binding of human brain nuclear proteins by electrophoretic mobility shift assay (EMSA). The minor G-allele was associated with significantly greater expression levels of firefly luciferase than the major A-allele of SNP rs569356 (P=0.003). EMSA also showed specific gel shift bands, suggesting that SNP rs569356 is situated in the binding site of potential transcription factors. These results suggest that the minor G-allele of SNP rs569356 may enhance transcription factor binding and increase OPRD1 expression.

Citing Articles

Translation of genome-wide association study: from genomic signals to biological insights.

Bruner W, Grant S Front Genet. 2024; 15:1375481.

PMID: 39421299 PMC: 11484060. DOI: 10.3389/fgene.2024.1375481.

Functional genetics reveals the contribution of delta opioid receptor to type 2 diabetes and beta-cell function.

Meulebrouck S, Merrheim J, Queniat G, Bourouh C, Derhourhi M, Boissel M Nat Commun. 2024; 15(1):6627.

PMID: 39103322 PMC: 11300616. DOI: 10.1038/s41467-024-51004-6.

Epigenetic Modulation of Opioid Receptors by Drugs of Abuse.

Reid K, Lemezis B, Hou T, Chen R Int J Mol Sci. 2022; 23(19).

PMID: 36233105 PMC: 9569510. DOI: 10.3390/ijms231911804.

A review of the existing literature on buprenorphine pharmacogenomics.

Meaden C, Mozeika A, Asri R, Santos C Pharmacogenomics J. 2020; 21(2):128-139.

PMID: 33154520 DOI: 10.1038/s41397-020-00198-1.

Prefrontal cortex eQTLs/mQTLs enriched in genetic variants associated with alcohol use disorder and other diseases.

Lin H, Wang F, Rosato A, Farrer L, Henderson D, Zhang H Epigenomics. 2020; 12(9):789-800.

PMID: 32496132 PMC: 7607393. DOI: 10.2217/epi-2019-0270.

References

Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G . Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry. 2005; 62(1):57-64. DOI: 10.1001/archpsyc.62.1.57. View

Xu K, Liu X, Nagarajan S, Goldman D . Relationship of the delta-opioid receptor gene to heroin abuse in a large Chinese case/control sample. Am J Med Genet. 2002; 110(1):45-50. DOI: 10.1002/ajmg.10374. View

Gorelick D, Kim Y, Bencherif B, Boyd S, Nelson R, Copersino M . Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry. 2005; 57(12):1573-82. DOI: 10.1016/j.biopsych.2005.02.026. View

Nielsen C, Simms J, Pierson H, Li R, Saini S, Ananthan S . A novel delta opioid receptor antagonist, SoRI-9409, produces a selective and long-lasting decrease in ethanol consumption in heavy-drinking rats. Biol Psychiatry. 2008; 64(11):974-81. PMC: 3888668. DOI: 10.1016/j.biopsych.2008.07.018. View

Sinclair J . Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 2001; 36(1):2-10. DOI: 10.1093/alcalc/36.1.2. View

Stengaard-Pedersen K . Comparative mapping of opioid receptors and enkephalin immunoreactive nerve terminals in the rat hippocampus. A radiohistochemical and immunocytochemical study. Histochemistry. 1983; 79(3):311-33. DOI: 10.1007/BF00491768. View

Reed S, Staley E, Mayginnes J, Pintel D, Tullis G . Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J Virol Methods. 2006; 138(1-2):85-98. DOI: 10.1016/j.jviromet.2006.07.024. View

Shippenberg T, Chefer V, Thompson A . Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine. Biol Psychiatry. 2008; 65(2):169-74. PMC: 3832215. DOI: 10.1016/j.biopsych.2008.09.009. View

Bodnar R . Endogenous opiates and behavior: 2006. Peptides. 2007; 28(12):2435-513. PMC: 2693002. DOI: 10.1016/j.peptides.2007.09.002. View

10.

Williams T, Davies S, Taylor L, Daglish M, Hammers A, Brooks D . Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. Eur Neuropsychopharmacol. 2009; 19(10):740-8. DOI: 10.1016/j.euroneuro.2009.06.007. View

11.

Zhu Y, King M, Schuller A, Nitsche J, Reidl M, Elde R . Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron. 2000; 24(1):243-52. DOI: 10.1016/s0896-6273(00)80836-3. View

12.

Corbett A, Henderson G, McKnight A, Paterson S . 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol. 2006; 147 Suppl 1:S153-62. PMC: 1760732. DOI: 10.1038/sj.bjp.0706435. View

13.

Tournamille C, Colin Y, Cartron J, Le Van Kim C . Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet. 1995; 10(2):224-8. DOI: 10.1038/ng0695-224. View

14.

Udalova I, Richardson A, Denys A, Smith C, ACKERMAN H, Foxwell B . Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol. 2000; 20(24):9113-9. PMC: 102169. DOI: 10.1128/MCB.20.24.9113-9119.2000. View

15.

Zhang H, Kranzler H, Yang B, Luo X, Gelernter J . The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry. 2007; 13(5):531-43. PMC: 3163084. DOI: 10.1038/sj.mp.4002035. View

16.

Gelernter J, Kranzler H . Variant detection at the delta opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. Hum Genet. 2000; 107(1):86-8. DOI: 10.1007/s004390000340. View

17.

Spanagel R, Herz A, Shippenberg T . Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A. 1992; 89(6):2046-50. PMC: 48593. DOI: 10.1073/pnas.89.6.2046. View

18.

Franke P, Nothen M, Wang T, Neidt H, Knapp M, Lichtermann D . Human delta-opioid receptor gene and susceptibility to heroin and alcohol dependence. Am J Med Genet. 1999; 88(5):462-4. DOI: 10.1002/(sici)1096-8628(19991015)88:5<462::aid-ajmg4>3.0.co;2-s. View

19.

Mayer P, Rochlitz H, Rauch E, Rommelspacher H, Hasse H, Schmidt S . Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport. 1997; 8(11):2547-50. DOI: 10.1097/00001756-199707280-00025. View

20.

Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A . MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005; 21(13):2933-42. DOI: 10.1093/bioinformatics/bti473. View